Updated guidance on LDL-C estimation, ApoB, lipoprotein(a) and PREVENT scoring signals a more individualized approach to cardiovascular risk assessment and prevention.
Video Highlights
Modern LDL-C estimation equations reduce misclassifications and improve treatment decisions.
ApoB measurement can refine risk assessment beyond LDL cholesterol by estimating atherogenic particle number, particularly when LDL cholesterol and ApoB may be discordant, such as in patients with metabolic syndrome or type 2 diabetes.
Lipoprotein(a) is a genetically determined risk factor associated with cardiovascular risk independent of LDL cholesterol and traditional risk factors.
The updated guidelines recommend measuring lipoprotein(a) at least once for risk estimation in patients with risk factors and considering cascade screening in familial hypercholesterolemia or premature atherosclerotic cardiovascular disease.
Reproductive history has greater prominence as a cardiovascular risk enhancer. Adverse pregnancy outcomes, including preeclampsia and gestational diabetes, can help identify patients who may face elevated long-term cardiovascular risk.
Risk categories derived from the PREVENT score should not be interpreted using the former pooled cohort equation thresholds. The revised cutoffs reflect differences in calculation and improved risk estimation rather than a change in patients’ underlying risk.
In this video, Dr. Sadeer Al-Kindi, preventive cardiologist at Houston Methodist, reviews key updates in contemporary lipid management and cardiovascular risk assessment, emphasizing the transition from the Friedewald equation to newer LDL-C estimation methods with improved analytical performance. The discussion highlights the expanding role of ApoB and lipoprotein(a) as biomarkers that may refine risk stratification beyond traditional LDL-C measurements, particularly in patients with residual or discordant risk. Additional attention is given to reproductive risk enhancers, underscoring the growing recognition of adverse pregnancy outcomes as important determinants of long-term cardiovascular health. The presentation concludes with practical considerations for applying the PREVENT score, including interpretation of revised risk categories and their role in personalized preventive cardiology.